Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director BIENAIME JEAN JACQUES
Keros Therapeutics | 3: Initial statement of beneficial ownership of securities-Director BIENAIME JEAN JACQUES
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GORDON CARL L
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director GRAY MARY ANN
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Knowles Julius
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Nussbaum Ran
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Kariv Tomer
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Seth Alpna
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Farzan Nima
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Seehra Jasbir
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Seehra Jasbir
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Regnante Keith
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Rovaldi Christopher
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Cooper Simon Peter
Keros Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Alkeon Capital Management, LLC(5.0%),Panayotis D. Sparaggis(5.0%)
Keros Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(12.931%),Abigail P. Johnson(12.931%)
Keros Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(6.8%)
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Regnante Keith
Keros Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Advisors LLC(4.2%),OrbiMed Capital GP VII LLC(3.7%), etc.
Keros Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Regnante Keith
No Data